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Abstract: Vaginal infections such as bacterial vaginosis (BV), chlamydia, gonorrhea, genital herpes,
candidiasis, and trichomoniasis affect millions of women each year. They are caused by an overgrowth
of microorganisms, generally sexually transmitted, which in turn can be favored by alterations in the
vaginal flora. Conventional treatments of these infections consist in systemic or local antimicrobial
therapies. However, in the attempt to reduce adverse effects and to contrast microbial resistance
and infection recurrences, many efforts have been devoted to the development of vaginal systems
for the local delivery of antimicrobials. Several topical dosage forms such as aerosols, lotions,
suppositories, tablets, gels, and creams have been proposed, although they are sometimes ineffective
due to their poor penetration and rapid removal from the vaginal canal. For these reasons, the
development of innovative drug delivery systems, able to remain in situ and release active agents
for a prolonged period, is becoming more and more important. Among all, nanosystems such as
liposomes, nanoparticles (NPs), and micelles with tunable surface properties, but also thermogelling
nanocomposites, could be exploited to improve local drug delivery, biodistribution, retention, and
uptake in vulvovaginal tissues. The aim of this review is to provide a survey of the variety of
nanoplatforms developed for the vaginal delivery of antimicrobial agents. A concise summary of the
most common vaginal infections and of the conventional therapies is also provided.
Keywords: vaginal infections; antimicrobials; drug delivery systems; nanocarriers; local therapies
1. Introduction
The vagina is a muscle-membranous canal that extends from the vulva to the cervix.
The wall of the vagina includes different layers: an inner mucosal tissue, consisting of a
stratified squamous epithelium, a middle smooth muscle layer made of longitudinal and
circular fibers, an external coat of connective tissue, and the peritoneum [1]. The vagina is
involved in several functions such as sexual functions, but also in active immunologic and
anatomically mediated processes essential for maintaining a microenvironment ideal for
“normal” bacteria [2]. In particular, many studies have demonstrated that several immune-
related cells and receptors are present in the vagina, helping the microbial environment.
There are five major types of vaginal microbiota, known as community state types (CSTs).
In four of these (CST-I, -II, -III, -V), Lactobacillus spp. is the predominant species; CST-IV,
instead, is composed of a mixture of several facultative anaerobes, including Gardnerella,
Atopobium, and Prevotella. The frequency of these CSTs is different according to the ethnic
backgrounds. Alterations in normal composition and functions of vaginal flora are involved
in the development of several vaginal diseases such as bacterial, fungal, and viral vaginosis
and can also increase the risk of acquiring sexually transmitted infections such as HIV, as
demonstrated by some studies [3].
Female reproductive tract-related diseases to (FRT) affect more than 10 million people
each year. Their symptoms often include itching, burning, pain, and dyspareunia, and are
responsible for significant distress for patients [4].
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Standard treatment options are numerous and mainly consist in antimicrobial drugs,
systemically administered, although topical treatments can also be prescribed. Some
clinical trials comparing oral with topical route demonstrated that women experienced
similar cure rate, but those using the intravaginal antimicrobial agents resulted in being
more satisfied with the treatment [5,6].
In addition, several oral antimicrobial therapies are responsible for side effects, in-
cluding gastrointestinal disorders and candida infection. Moreover, low adherence to oral
therapy may determine treatment failure, which in turn can increase the risk of recurrence
or drug resistance. On the contrary, intravaginal treatments offer several advantages,
including the capability of by-passing first metabolism, the ease of administration, and the
reduction of side effects.
Many researchers have shown that the vagina is an underutilized route for drug
administration, and therefore remarkable efforts have recently been made to optimize this
promising route of administration [7,8] for both local and systemic actions. In fact, systemic
vaginal absorption of a variety of therapeutic molecules (proteins, small interfering RNAs,
peptides, vaccines, oligonucleotides, antigens, and hormones) have been explored in recent
years [9].
To date, a large number of topical dosage forms such as lotions, aerosols, gels, creams,
suppositories, ovules, and tablets have been proposed for vaginal drug delivery but their
effectiveness is highly limited by poor permeability across the vaginal wall and rapid
removal from the vaginal canal, further influenced by the presence of hormones [10].
Accordingly, multiple and frequent local administrations are required to compensate for
the rapid removal of drug carrier, leading to an increment of drug side effects and a
reduction of patient compliance.
For these reasons, the vaginal delivery of drugs remains a challenge, and the discovery
of novel effective local treatments able to remain in situ and release active agents for a
prolonged period of time is gradually gaining interest [11].
In the first part of this review, we propose a focus on the main vaginal infections
and their conventional treatments, while the second part focuses on the most recent
innovative strategies, particularly the nanoplatforms, developed to optimize the topical
vaginal delivery of antimicrobials.
2. Vaginal Infections and Conventional Treatments
The vagina can be affected by several inflammations or infections caused mainly by
bacteria but also by yeast, viruses, and parasites. Moreover, there are several associated
risk factors such as sociodemographic characteristics, routine hygienic practices, hormonal
imbalance, and lifestyle-related behaviors. A summary of the most commonly encountered
vaginal infections, pathogens, and conventional treatments is presented in Table 1.
2.1. Bacterial Infections
Bacterial vaginosis (BV) is a common cause of medical problems whose exact etiology
remains uncertain, although an interaction between microbial ecosystem and human
host seems to occur; in particular, Gardnerella vaginalis replaces the resident Lactobacillus
species. Risk factors are represented by vaginal douching; African American race; and,
above all, multiple sexual partners. On the contrary, the use of hormonal contraceptive
or condom could reduce the incidence of BV. Generally, BV treatment involves the use of
antibacterial drugs, [12] especially metronidazole, tinidazole, secnidazole, and clindamycin.
Furthermore, some alternative approaches such as the employment of probiotics/prebiotics,
the local acidification, or the use of essential oils are under study [13].
Chlamydia is a sexually transmitted bacterial infection due to Chlamydia trachomatis, a
Gram-negative obligate pathogen. In about 80% of affected women, chlamydia is asymp-
tomatic, and in the other cases, vaginal discharge, mucopurulent endocervical discharge,
and easily induced endocervical bleeding are the most common symptoms. If untreated,
the infection may last for 4 years. Furthermore, chlamydia infections can lead to infertility,
Nanomaterials 2021, 11, 311 3 of 29
chronic pelvic pain, and ectopic pregnancy, and can also increase the risk of developing
cervical cancer [14]. The first-choice treatment is based on the oral administration of
azithromycin (1 g oral single dose) or doxycycline (100 mg orally twice a day for 7 days).
However, azithromycin is not available in some settings, and thus erythromycin, ofloxacin,
or levofloxacin can be administered as alternatives. Erythromycin exhibits noteworthy side
effects that may reduce compliance, and levofloxacin and ofloxacin are high-cost drugs [15].
Table 1. Pathogens and treatments of vaginal infections.
Pathogen Recommended Treatments Alternative Treatments
Bacterial infections
Gardnerella vaginalis
Metronidazole 400 mg OR 2-daily × 7 days,
0.75% metronidazole vaginal gel, or 2%
clindamycin vaginal cream
Use of probiotics or prebiotics
Use of essential oils
Local acidification
Chlamydia trachomatis Azithromycin 1 g OR doses × 7 days ordoxycycline 100 mg OR × 7 days Erythromycin, ofloxacin, levofloxacin





Treponema pallidum Benzathine penicillin G IM 3-weekly,ceftriaxone or tetracyclines Azithromycin
Viral infections
Herpes simplex Acyclovir, valacyclovir, or famciclovir ORdoses × 7–10 days
Foscarnet or cidofovir (in case of
acyclovir resistance)
Human papilloma virus
Topical application (cream/gel) of
trichloroacetic acid or podophyllin
derivatives or imiquimod
Cryotherapy, electrocautery, laser, or
surgical excision
Human immunodeficiency virus type 1 Inhibitors of reverse transcriptaseand protease
Combination of several antiviral agents;
















Gonorrhea is a sexually transmitted disease due to Neisseria gonorrhoeae, which is
a Gram-negative diplococcus. It is often asymptomatic in females, but dysuria, vaginal
discharge, abnormal uterine bleeding, dyspareunia, lower abdominal, and rectal pain are
usually detected as symptoms. Furthermore, without a proper treatment, pelvic inflam-
matory disease, chronic pain, and facilitation of HIV transmission can be observed [16].
First-line treatment consists in the use of antibiotics (cefixime or ceftriaxone) administered
orally or intramuscularly. In cases of drug resistance, a dual antibiotic treatment could
be a possible option, even though both approaches often fail. After all, Neisseria gonor-
rhoeae antimicrobial resistance is an increasing issue, and for this reason, new antibiotics
are being developed, e.g., macrolide drugs, tetracycline derivatives, and broad-spectrum
fluoroquinolones [17,18].
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Syphilis is caused by the bacterium Treponema pallidum subspecies pallidum and, like
gonorrhea and chlamydia, it is a sexually transmitted infection; it can also be passed to the
fetus during pregnancy or during vaginal birth. Syphilis is divided into three stages, with
the first being characterized by a painless ulcer in which the infectious bacteria are located.
The sore can last for several weeks, during which the infection can spread in cases of contact.
If untreated, the primary syphilis can evolve to secondary syphilis, characterized by a rash
diffused on several parts of the body that is sometimes accompanied by fever, fatigue,
weight loss, enlarged lymph nodes, etc. Infected and untreated people can develop the
third stage of syphilis, characterized by severe damages to vital organs and consequently
problems such as dementia, paralysis, and loss of sight.
Furthermore, in a pregnant woman, untreated syphilis represents a potential risk to
the fetus, and it is also well recognized as interacting synergistically with HIV [19].
The treatment of syphilis depends on the stage of infection, with Treponema pallidum
being particularly susceptible to penicillin. Indeed, the standard therapy consists in
benzathine penicillin G (2.4 million U) intramuscularly administered in three weekly doses;
intramuscular ceftriaxone or oral tetracyclines are also considered, but there is less evidence
of their efficacy. If all other options are not feasible, azithromycin in single 2 g oral dose is
suggested [20].
Overall, chlamydia, gonorrhea, and syphilis are the most world spread sexually
transmitted infections—all are caused by bacteria and are generally curable with antibiotics,
but unfortunately the antibiotic resistance of these pathogens is rapidly growing especially
in the case of gonorrhea. In this context, prompt treatment, prevention campaigns, and
novel treatment options are becoming crucial.
2.2. Viral Infections
Herpes genitalis is a sexually transmitted disease caused by the Herpes simplex virus
(HSV), which can be subdivided in two types: HSV-1 (whose diffusion is growing) and
HSV-2 (the most common form). HSV-1 infections mostly occur during childhood, while
HSV-2 infections generally rise after puberty. Furthermore, herpes genitalis can manifest as
primary or recurrent infection. Burning pain, fever, cervicitis, and lymphadenopathy are
among the most common symptoms. Factors such as fever, UV light, stress or trauma, and
immunogenic predisposition can act as triggers. Nevertheless, both symptoms and clinical
recurrence are less severe in comparison with primary infection. First-line treatments are
antivirals like acyclovir, valacyclovir, and famciclovir.
Systemically administered foscarnet and cidofovir (off-label) have been considered
as alternative treatments to overcome resistance episodes. Unfortunately, they exhibit
several adverse reactions such as urogenital ulcers, renal dysfunction, and nephrotoxicity.
However, topical application of cidofovir gel or 1% foscarnet cream represents an attractive
tool for the treatment of herpes genitalis. Currently, a new class of drugs called “helicase
blockers” is under study, showing good results in preliminary tests [21,22].
Human papilloma virus (HPV) is probably the most common sexually transmitted
infection in the world, improving the risk of cervical cancer and genital warts when the
infection persists. HPV could infect squamous cells such as vaginal and anal epithelium,
but also skin, oral, and nasal epithelium. The treatment for HPV infections is limited
and influenced by viral latency and recurrent reinfections that reduce in a significant way
the success of the treatment. In presence of a benign HPV lesion (genital warts), tissue
destruction could be reached through thermal, electric, or chemical means. Four to six
weeks are required before expecting benefit. Several strategies have been studied for the
treatment of HPV infections. Among all, trichloroacetic acid, podophyllin derivatives,
and imiquimod are the most used agents for chemical therapy, but other approaches, e.g.,
cryotherapy, laser, electrocautery, and surgical excision, are also diffused [23]. However,
all above-mentioned treatments exhibit drawbacks such as short-term pain from healing
to hypopigmentation and scarring; rarely, hyperesthesia, chronic pain, and dyspareunia
are observed.
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AIDS (acquired immune deficiency syndrome) is probably one of the most dangerous
human diseases. It is caused by the Human immunodeficiency virus type 1 (HIV-1), which
is primarily transmitted through heterosexual intercourse or from mother to child. The
risk of being infected with HIV during sexual contact is higher for women than from men,
mainly due to the fact that the large surface area of the vagina is highly exposed to the
virus. The symptoms of HIV/AIDS are similar in women and men. However, infections
of the female reproductive organs may be more frequent and severe in women with HIV
infection. Moreover, a causal relationship between vaginal lesions and susceptibility to
HIV-1 infection has been confirmed [24].
These premises highlight the need to combine local and systemic therapy aimed at
both preventing and treating vaginal diseases, combined with new systemic antiviral and
vaccine therapies.
The HIV-1 life cycle is complex, with duration and results that depend on targeted
and activated cells [25]. From the 1990s, the treatment of HIV-1 has been focused on the use
of inhibitors of reverse transcriptase, as well as on protease inhibitors, which are essential
enzymes for HIV-1 life cycle, alone or in association.
The first class could be further subdivided in nucleoside/nucleotide derivatives
(NRTIs) and non-nucleoside compounds (NNRTIs), which are non-competitive inhibitors.
HIV-1 protease inhibitors are the second group of drugs for HIV therapy and the
largest group of inhibitors (currently eight compounds are used).
Other drugs that inhibit different steps of the viral life cycle have been developed, for
example, virus cell entry inhibitors, among which enfuvirtide and maraviroc are currently
the only approved. A similar mechanism of action is exhibited by natural compounds such
as marine algae polysaccharides, chitosan derivatives, or sulfated polysaccharides, but
they are not approved as drugs [26].
However, as previously mentioned, HIV-1 standard therapy shows some drawbacks,
mainly due to resistance development. For this reason, the combination of several antiviral
agents has become more and more advantageous. Nevertheless, high toxicity levels are
associated to long-term treatment, e.g., renal and hepatotoxicity, diabetes mellitus, and
immunodeficiency, which might be reduced by periodic interruption of the treatment
interruptions, even if this hypothesis requires further exploration [25]. Moreover, the use of
microbicides to prevent rectal and vaginal transmission of HIV-1 is becoming noteworthy.
In this review, we focalized our attention mainly on the development of novel drug
delivery systems for vaginal drug administration of anti-HIV-1 compounds.
2.3. Fungal Infections
Vulvovaginal candidiasis (VC) is a fungal infection caused by yeasts of Candida species
that could extend to other female organs. Candida albicans is the most isolated pathogen,
responsible for 50–70% of systemic fungal infections. Diabetes mellitus, obesity in associa-
tion with intertrigo due to rubbing and sweating, high estrogen levels (particularly during
pregnancy), genetic factors, atopic diathesis, type 1 allergies, and immune suppression are
predisposing host factors. On the contrary, there is no connection between the frequency
of antibiotic administration and the development of VC. Common treatments are based
on the administration of antifungal agents such as imidazole class (ketoconazole, chlortri-
mazole, fluconozole, etc.), and echinocandins (capsofungin, micafungin, anidulafungin),
amphotericin B, and flucytosine, usually administered in association. Allylamines such
as terbinafine and naftifine or griseofulvin, but also the orally administered probiotics
represent other alternatives to common treatment. However, all traditional antimycotic
agents do not have a broad spectrum of action and exhibit high toxicity/low bioavailability,
requiring further studies to improve current therapies [27].
2.4. Parasitic Infections
Trichomoniasis is a sexually transmitted infection considered responsible for high
reproductive morbidity and a promoter of both HIV infection and transmission. It is caused
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by Trichomonas vaginalis, an obligate parasite that phagocytizes vaginal epithelial cells, ery-
throcytes, and bacteria, and is itself ingested by macrophages. At first, Trichomonas vaginalis
infects the squamous epithelium of the genital tract with a 4–28-day incubation period.
Then, the infection can last also for months or even years and can be asymptomatic (up to
50%) but also severe, with serious sequelae, especially in women [28]. Standard treatments
consist in 2 g one-dose oral administration of metronidazole or tinidazole. Although both
are the most effective drugs for treating Trichomonas vaginalis infection, in case of hypersen-
sitivity to 5-nitroimidazole drugs, disulfiram and nithiamide might represent alternatives.
However, there are only limited data on alternatives to nitroimidazole derivatives, and thus
new antitrichomonal agents or new pharmaceutical formulations are needed. Currently,
prevention methods using condoms or local intravaginal formulations remain the most
reliable form of protection, but certainly the development of vaccines could be a winning
strategy [29].
3. Local Drug Delivery Systems for Vaginal Infections: From Conventional to
Innovative Strategies
As previously reported, in developing novel vaginal drug delivery systems, the
physiological characteristics of the vagina must be accurately considered because they
could influence drug dissolution and transport across the membranes. Indeed, like other
mucosal delivery systems, when drugs are administered through the vaginal route they are
absorbed transcellularly (diffusion through cells), paracellularly (through tight junctions),
or vesicularly, or are transported by receptors. Furthermore, changes in vaginal epithelium
thickness, composition, volume, viscosity, and pH of vaginal fluid may influence drug
absorption either negatively or positively. For example, the absorption of poorly water-
soluble drugs could be increased in the presence of high volumes of the vaginal fluid; on the
other hand, an increase in its viscosity can represent a barrier to drug absorption. Among
biological factors, also enzymes (mainly proteases), enzyme inhibitors, proteins, amino
acids, lactic acid, acetic acid, glycerol, urea, glycogen, and ions may affect intravaginal
drug formulation stability or drug absorption. In addition, drug properties, e.g., molecular
weight, lipophilicity, ionization, and surface charge, are other important parameters that
need to be considered. Traditionally, solutions, ovules, foams, gels, and tablets have been
used as vaginal formulations, but it was demonstrated that drug distribution varies in a
meaningful way with the nature of the formulation. Among all, solutions, suspensions,
and foams show better properties compared to tablet forms.
At the same time, bioadhesive formulations ensure a prolonged residence time in
the vaginal cavity. In Table 2, we report some of the most employed commercial vaginal
dosage forms [30].
Generally, the rate of drug distribution after intravaginal administration and the
ability of the formulation to coat the whole organ are hard to be quantified. Moreover,
mucosal surface properties play an important role in influencing biodistribution, retention,
and uptake across the mucus. For example, surface chemistry and charge could influence
attraction or repulsion between mucin fibers.
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Table 2. Some examples of commercial vaginal products for local drug delivery [30,31].
Product Use Dosage Form Side Effects
Metrogel-vaginal




(tioconazole) Anti-fungal, candida infection Ointment
Shortness of breath; swelling of lips, face,
or tongue
Trivagizole
(clotrimazole) Anti-fungal infection Cream Partners may experience minor skin irritation
Zidoval
(Metronidazole) BV Gel
Irritation, vaginal discharge, itching, burning,
numbness, abdominal pain, to avoid in
patients with blood dyscrasias
Dalacin
(clindamycin) BV Cream
Overgrowth of non-susceptible organisms
(yeasts), diarrhea, pseudomembranous colitis,
interactions with protection for sexually
transmitted disease/contraceptive
Flagystatin
(metronidazole + nystatin) BV Ovules
Cross-resistance, sensitizations, vaginal
burning, local irritation, spot on the skin
around the knees, fatigue
Canesten
(clotrimazole) Candidiasis Cream
Allergic reactions, blisters, discomfort, pain,
edema, erythema, irritation, rash,
stinging, burning
Gyno-Daktarin
(miconazole nitrate) Candidiasis Ovules
Rash, genital pruritus, burning sensation,
vulvovaginal discomfort, dysmenorrhea
Neo-Penotran
(metronidazole + miconazole) Trichomoniasis Ovules





endogenous bacteria Ovules No undesirable effects have been reported
FloraFemme
(strains of lactobacilli and
bifidobacteria)
Supplement of
endogenous bacteria Ovules No undesirable effects have been reported
To overcome all these limitations, there is the need to develop novel drug delivery
systems on the basis of nanotechnologies to increase drug physical stability and bioactivity,
reduce toxicity, and enhance patient compliance. However, particular attention should
be paid to the size of these nanosystems. Indeed, particle diameters control the ability
to fit within the mucin mesh pores. Moreover, the ability to form aggregates potentially
affects the diffusion or the immobilization of the particles across mucus. In fact, particle
self-binding could lead to the formation of aggregates immobilized on the surface that
exhibit a mucoadhesive behavior. This property improves the residence time of the system,
providing its intimate contact with the mucosa; in addition, the concentrations of NPs onto
mucus could influence its normal structure causing the collapse of mucin fibers [32].
Nanosystems such as liposomes, nanoparticles (NPs) (including solid lipid NPs, poly-
meric NPs, or inorganic NPs), and micelles could be exploited to improve local vaginal
drug delivery. Different types of biocompatible and biodegradable polymers already ap-
proved by the U.S. Food and Drug Administration (FDA) and by other authorities have
been proposed for controlled drug delivery at mucosal surfaces. Among these, poly(lactic-
co-glycolic acid) (PLGA), cellulose derivatives, triblock copolymers of poly(ethylene oxide)
(PEO)/poly(propylene oxide) (PPO) (PEO-PPO-PEO), polycaprolactone (PCL), polyacry-
lates, poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA), and alginate have been
studied either as additives or as matrices of NPs.
It is well known that the use of PVA as surface stabilizer or the surface coating with
PEG chain contributes to vaginal adhesion and promotes the formation of bonding with
the hydrophobic regions of mucin, enabling the rapid diffusion in cervicovaginal mucus.
However, although the above-mentioned mucoadhesive polymers can promote vaginal
drug retention, they could lead to mucus disruption and to the loss of its barrier properties
against xenobiotics and pathogens. The intrinsic toxicity of these polymers should also be
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taken into account, even if in general they are eliminated by mucus turnover and discharge,
or by natural cell shedding, when epithelial penetration occurs [33]. An alternative is
represented by thiolated hyaluronic acid, preactivated with 6-mercaptonicotinamide, which
exhibits enhanced stability and mucoadhesive properties without toxicity, as demonstrated
by a study of Nowak et al. (2014) [34].
During the last decades, various types of nanosystems have been explored for vaginal
drug delivery (mucoadhesive, non-mucoadhesive, or mucus-penetrating) in an attempt to
overcome the limitations of conventional dosage forms. The most innovative forms are
discussed in the following paragraphs, with a particular attention to the nanotechnology-
based antimicrobial strategies.
3.1. Vaginal Drug Delivery Systems for Bacterial Infections
3.1.1. Bacterial Vaginosis
Vaginal delivery of clindamycin or metronidazole is one of the commonest therapies
in the treatment of BV, but its efficacy is not ideal. Several researchers are working to
improve existing formulations or to create new dosage forms (Figure 1).
In situ gelling systems such as hydrogels represent a valuable alternative to conven-
tional gels due to their ability to provide the most convenient liquid application in the
field of topical delivery and to remain in situ for a prolonged period. The liquid topically
applied turns into gels because of physical and/or chemical change such as pH variations,
concentration of calcium ions, or temperatures, amongst others. To obtain a sustained
release, one can either disperse the drug in the gel or initiate an interaction between the
drug and an oil phase included in the gel.
With this aim, Chopra et al. (2007) designed and evaluated a new polyherbal antimi-
crobial mucoadhesive drug delivery system using three different grades of Carbopol resins,
which showed excellent bioadhesive properties on the mucosa surface [35].
Multiple water–oil-in-water (W1/O/W2) emulsions are an alternative system that can
entrap substances in the inner aqueous phase, protecting them from the outer environment
and modulating their release; moreover, several actives can be located in the different
compartments. These systems are easy-to apply formulations with efficient, light, non-
greasy, and non-sticky textures that may facilitate the application and prevent irritation
and burning in the vulvovaginal region [36,37]. Özer et al., in 2007, formulated two
multiple emulsions containing metronidazole and ornidazole in different aqueous phases,
monitoring both drug release in acidic/alkaline medium to understand the role played
by pH on the release. A proper release was observed in alkaline medium, which is
convenient for vaginal infection, and both the systems were found to be locally effective in
the vagina [38].
In addition, other innovative emulsions have been recently investigated for local drug
administration in vaginal diseases. Mucoadhesive water in silicone emulsions (W/S emul-
sions) can resist the clearance effect of vaginal fluid by promoting the formation of a
highly resistant adhesive layer. This characteristic makes W/S emulsions a good alter-
native to vaginal hydrogels, whose rapid swelling in the aqueous medium determines
loss of consistence and bioadhesion. Moreover, W/S emulsions have good rheological,
mechanical, and organoleptic properties; high biocompatibility; and low toxicity. For
these reasons, Campaña-Seoane et al. (2019) studied the in vivo behavior and drug ab-
sorption/distribution to the sexual organs of a W/S mucoadhesive emulsion containing
ciprofloxacin, which is a broad-spectrum antibiotic frequently used in the treatment of
sexual infections. As expected, the system exhibited an excellent in vivo bioadhesion and
high resistance to vaginal clearance with a constant ciprofloxacin release during at least
6 h, which showed W/S emulsions to be a potential tool for the treatment of sexual tissue
infections [39].
Lastly, liquid crystals represent an emerging class of drug delivery systems consti-
tuted by polar lipids that can reorganize themselves into 3D structures in water. Liquid
crystals have a malleable structure that could be controlled to allow both sustained drug
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release and ease of administration. Recently, some authors (2019) evaluated the controlled
delivery into cells of ciprofloxacin encapsulated in liquid crystals, demonstrating that they
significantly enhance bacterial killing compared to free drug formulation and highlighting
their potential use for the treatment of FRT infections and/or topical administration for the
upper infections [40].
Besides all these platforms developed to increase active agents’ delivery and retention
time in the FRT for the treatment of BV, in recent years, NPs have gained increasing atten-
tion.
Mucoadhesive multiparticulate systems exhibit several advantages for vaginal admin-
istration compared to other commonly used dosage forms because they can cover a wider
mucosa area and allow a prolonged drug permanence on its surface and a sustained release
over a long period of time. They offer several advantages such as drug protection from
degradation in the acidic vaginal microenvironment, sustained release, high entrapment,
and localized delivery of both hydrophobic and hydrophilic agents. Polymeric NPs, with
their small sizes (from 70 to 300 nm), exhibit good physical properties and are suitable for
the delivery to the FRT. Surface modifications, e.g., ligands conjugation or adsorption, im-
prove retention, diffusion, and cell-specific targeting. Polymeric NPs are made of non-toxic
and non-inflammatory polymers, making them biocompatible systems [41]. In a recent
work by Marciello et al. (2019), chitosan NPs encapsulated in hydrophilic freeze-dried
cylinders were developed for the delivery of a peptide drug. They were assessed to im-
prove the peptide adhesion to the vaginal mucosal epithelium. In addition, hydrophilic
freeze-dried cylinders enabled the application and the quick release of NPs into the vaginal
zone after the contact with the aqueous vaginal medium, promoting peptide penetration
inside vaginal mucosa [42].
However, although several NPs show greater mucoadhesivity than conventional
systems, they hardly overcome the mucus barrier requiring high administration doses to
reach the underlying tissues. A promising approach overcoming this drawback seems
to derive from “stealth” NPs. In a study by Sims et al. (2019), stealth PEG-coated NPs
exhibited appropriate mucus-penetrating properties as well as improved drug retention
and transport. Tests performed on PLGA NPs showed that prolonged retention profiles for
24 h were obtained with the greatest percentage of PEG coating (5, 8, 25%) [43].
Lastly, NPs could also be exploited for rapid diagnosis of vaginal infections. With
the aim of overcoming the high costs and time-consuming nature of diagnosis laboratory
methods, Hashemi et al. (2019) developed gold NPs conjugated with antibodies to be
used in an agglutination test for the detection of vaginal infections. Results demonstrated
that gold NP tests are simple, accurate, and cost-effective, being a potential way to detect
vaginal infections [44].
Another example of multiparticulate systems is represented by chitosan–alginate
microspheres such as those formulated by Maestrelli et al. (2018) for the vaginal adminis-
tration of cefixime, used in order to overcome drawbacks following its oral administration.
The effect of increasing drug loading amount was investigated; mucoadhesion studies
reported that all formulations were able to remain in situ for more than 2 h (on excised
porcine vaginal mucosa), showing good adhesion properties. Entrapment efficiency grew
by increasing the starting loading drug concentration, reaching a plateau at the optimal
drug-to-polymer ratio. Microbiological studies confirmed the potential advantages of such
systems that can be administered inside a capsule by a commercially available vaginal
applicator. After capsule dissolution, the distribution of chitosan–alginate microspheres
occurs with a prolonged in situ activity of cefixime due to their good mucoadhesion and
extended release properties [45].
Chitosan/alginate can also be used for the development of complexes through the mix-
ing of polymeric solutions with different chitosan/alginate molar ratios and freeze-drying
the precipitates. They have been used to prepare chlorhexidine-loaded vaginal inserts.
Drug distribution; mucoadhesion; and in vitro water uptake, release, and microbiological
tests demonstrated that these systems can overcome messiness and leakage of formulations,
Nanomaterials 2021, 11, 311 10 of 29
increasing patient compliance. Moreover, the chlorhexidine digluconate release from this
insert can inhibit the pathogenic agents responsible for vaginitis [46].
Lastly, multiparticulate systems also include microbeads, such as those prepared by
Szymanska et al. (2019) via spray-drying method. Zidovudine, a water-soluble antiretro-
viral agent, was selected as a potential active agent to be applied as vaginal microbicide.
Rheological behavior, spreadability upon dilution, and drug dissolution profile were eval-
uated in vitro in a simulant vaginal fluid. In a second step, cytotoxicity was assessed on
human vaginal mucosa cell line VK2/E6E7. An initial rapid/moderate burst effect was
observed in formulations spray-dried at 120 ◦C and 160 ◦C, followed by a prolonged,
swelling-dependent drug release stage. The inlet spray-drying temperature is an impor-
tant factor since, through changing it, the swelling capacity and in vitro drug release of
microbeads could be easily modified. Moreover, zidovudine-loaded systems were able to
reduce cell viability after 24 h of incubation, being shown to be a promising microbicide
delivery platform for the delivery of water-soluble drugs into the vaginal environment [47].
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3.1.2. Chlamydia
NPs have gained increasing interest in the treatment of Chlamydia trachomatis. Metal-
based NPs, for example, exhibit antibacterial activity due to their ability to produce reactive
oxygen species damaging the bacteria and to bind to RNA or DNA, thereby hindering
microbial replication processes. Among all, silver NPs are the most diffused and described
in literature. They can penetrate bacterial cell walls, damaging the structure of cell walls
and resulting in cell death by producing free radicals or interacting with the thiol groups of
many bacteria vital enzymes. Moreover, they can interact with the phosphorus and sulfur
atoms of DNA, inhibiting DNA replication of the bacteria. NP shape and size have been
report d to influence the ntibacterial effects. In fact, smaller nanosized silver particles
seem to b more effective tha larger ones, and spherical shaped NPs exhibit enhanced
antibacterial activity in comparison with the triangle-shaped forms [48]. NPs could also be
used as a strategy to reduce vaginal infection of Chlamydia trachomatis.
A pilot study by Sangare et al. (1999) evaluated the in vitro anti-chlamydial activities of
liposome-encapsulated doxycycline and tetracycline in comparison with free drugs. Drug
loaded cationic, anionic, and neutral liposomes were prepared by sonication, showing
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a higher inhibitory effect on Chlamydia trachomatis growth than free doxycycline and
tetracycline. These results demonstrated that developed liposomal formulations can be
very useful as an alternative strategy for antimicrobial therapy [49].
More recently, Yang et al. (2017) [50] developed a novel combination therapy consist-
ing of siRNA-polyethylenimine-encapsulated NPs made of PLGA-PEG that are able to
knock down the expression of platelet-derived growth factor receptor-β (PDGFR-β) and
simultaneously induce autophagy through the encapsulation of a cationic polymer. In this
way, systemic adverse reactions and resistance caused by antibiotic oral administration can
be avoided. The use of PDGFR-β siRNA-PLGA-PEG NPs should start days before sexual
interactions due to the delayed onset of action of gene silencing by PDGFR-β siRNA. Its
use may continue in the long term since the gene knockdown effect of siRNA is temporary
and because the continuous intracellular level of siRNA needs to be maintained in order to
obtain sustained gene knockdown. However, the duration of administration and dosing
frequency must be determined by future in vivo and clinical studies. Moreover, in the
future, other potential receptors can be targeted simultaneously to enhance the prevention
efficacy. An interesting study found in the literature [51] reports the use of PLA-PEG
NPs for the sustained delivery of a Chlamydia trachomatis recombinant peptide to increase
systemic adaptive immune responses that are required by a vaccine candidate. Results
highlight PLA-PEG’s potential for vaccines due to the slow release and potentiated effects
to bolster immune response.
In a recent patent, folic acid- and/or fluorescence-labelled PLA-PEG NPs for imaging
chlamydia infection were described, wherein NPs targeted folic acid receptor-expressing
cells infected with chlamydia. In an imaging experiment, folic acid-conjugated NPs accu-
mulated in significantly high amounts in the genital tract [52].
3.1.3. Gonorrhea and Syphilis
The growing antibiotic resistance against gonorrhea emphasizes the need to identify
new antimicrobials. Chitosan has shown a wide spectrum of antimicrobial activity against
Gram-positive and Gram-negative bacteria. Its antimicrobial activity has been demon-
strated by different theories, but the exact mechanisms are still unknown. This suggests
that there is a potential for chitosan NPs as an antimicrobial agent against pathogens such
as gonococcus. In a study by Alqahtani et al. (2020) [53], chitosan NPs were formulated
and then characterized through examining their antimicrobial activity against Neisseria
gonorrhoeae. They revealed an anti-gonococcal activity against the tested strains, which
took place at specific concentrations, at which NPs reduced bacterial adhesion to cells
and were cytocompatible, confirming the therapeutic potential of chitosan NPs against
Neisseria gonorrhoeae.
In another study (2019), chitosan-based liposomes-in-hydrogel loaded with polyphe-
nols (resveratrol and epicatechin) were developed. Each polyphenol was singularly incor-
porated into the formulation. It appeared that when liposomes were incorporated into chi-
tosan hydrogel, the gel’s texture properties could be improved. In addition, the developed
systems displayed adequate mucoadhesive properties, achieving a prolonged retention
time; indeed, a prolonged and controlled release of the entrapped polyphenols was reached.
These formulations did not show direct toxic effect to living cells at considerable treatment
concentrations. Epicatechin showed enhanced anti-oxidative and anti-inflammatory activ-
ity at the highest concentrations when formulated in the liposomes-in-hydrogel system.
Moreover, chitosan helps the biological activities, making the developed system a potential
vaginal delivery platform for the treatment of localized infections and inflammations [54].
Finally, the encapsulation of octylglycerol into liposomes exerted an increased efficacy
against Neisseria gonorrhoeae compared to a conventional gel formulation. The efficacy was
maintained for over two months. Moreover, no toxicity was observed for the octylglycerol-
loaded liposomal formulation when tested ex vivo in a human ectocervical tissue model or
in vivo in a macaque model [55].
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Figure 2 summarizes the recently developed drug delivery systems for the local
treatment of chlamydia and gonorrhea.
As for syphilis, penicillin is the first-line treatment option; in particular, benzathine
penicillin G provides a convenient regimen in terms of ease of administration and with
demonstrated anti-treponemal activity. However, syphilis is an important and increasing
public health problem for which timely diagnosis is important to limit its clinical effects.
Recently, a novel quantum dot-based point of care test for syphilis has been developed [56].
Moreover, a Goldmag immune probe, as part of a NP-based colorimetric assay for the
detection of syphilis, has also been proposed [57]. In addition, tests have demonstrated
that polyelectrolyte-coated gold magnetic NPs are sensitive and selective when used in a
syphilis immunoassay, suggesting a possible use in point of care diagnostics for syphilis
screening [58].
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3.2. Vaginal Drug Delivery Systems for Viral Infections
Approved therapies for viral vaginal infections are based on the use of inhibitors of the
viral DNA replication. Although they are effective against primary infections, they cannot
protect against the viruses in the latent state, resulting in the reoccurrence of the diseases.
Thus, there is a considerable interest in discovering novel therapeutic approaches prefer-
entially acting through different mechanisms from those of the conventional approaches
(Figure 3).
3.2.1. Herpes Genitalis
Currently, either NPs or NP composites are under study to control HSV-2 infections.
As an example, zinc oxide NPs have been found to exhibit significant antiviral activity
in both the in vitro and in vivo mice model of HSV-2 infections. In a study by Antoine
et al. (2012), three different treatment modes were used: prophylaxis, therapeutic, and
neutralization. In all of the treatment modes, zinc oxide NPs showed promising results in
blocking HSV-2 infections [59,60]. Another study showed the possibility of using mucus-
penetrating NPs as antiviral agents—acyclovir monophosphate-loaded mucus-penetrating
NPs showed an increased drug retention and distribution, thus providing an effective
protection against HSV-2 challenge [61].
The anti-bacterial and antifungal properties of silver NPs have been also widely stud-
ied. Moreover, tannic acid exhibits antioxidative, anticancer, and antimicrobial properties,
preventing virus attachment, entry, and cell-to-cell spread, as reported by some studies.
Orlowski et al. (2014) developed tannic acid-modified silver NPs with good antiviral
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properties both in vitro and in vivo by direct blocking of viral attachment and penetration.
Altogether, the authors showed that tannic acid-modified silver NPs represents a potential
microbicide for HSV infection in the mucosal tissues [62]. The effective anti-viral proper-
ties with additional adjuvant properties boosted the anti-viral response, not only during
the primary infection, but also later upon recurrent infections [63]. In fact, silver NPs at
nontoxic concentrations can inhibit HSV-2 replication when administered prior to viral
infection or soon after initial virus exposure, suggesting that their mode of action occurs
during the early viral replication phases [64].
Other studies involved the development of drug-loaded PLGA NPs for the intravagi-
nal administration of siRNA for the prevention of genital HSV-2 infections in mice. PLGA
NPs were designed to interfere with HSV-2 infection by siRNA-mediated knockdown of
nectin, a host cell protein. In this way, the survival of mice, inoculated intravaginally with
a lethal dose of HSV-2 and treated with PLGA NPs, increased considerably to more than
28 days compared to the untreated mice. Furthermore, this system provides a safe delivery
platform that employs materials that are already approved by the FDA and that can be
modified to improve delivery of other microbicides [65]. In another study, ftibamzone-
loaded NPs significantly enhanced the solubility and absorption of ftibamzone compared
to free drug and had the potential to be used as an effective delivery system to treat genital
herpes [66].
A controlled release could also be reached using in situ gelling systems loaded with
polymeric NPs containing acyclovir. These Pluronic F127 gels exhibited enhanced per-
meability through vaginal membrane. Moreover, NPs showed improved viability for
vaginal epithelial cell lines. Significant enhancements in drug mean residence time and in
the relative bioavailability were observed in comparison with those of the pure drug. A
sustained in vivo drug release was demonstrated, ensuring the stability of the formulation
for clinical therapy in the female population [67].
3.2.2. Human Papillomavirus (HPV)
Due to their favorable characteristics, the use of liposomes as drug carrier represents a
possible tool for the treatment of HPV. In a study published in 2016, liposomes entrapping
interferon alpha-2b were PEGylated to allow them to penetrate mucus for a localized action
against HPV vaginal infections. The release rate performed in vitro on a model membrane
showed a negligible release of interferon alpha-2b from both the control and the liposomal
formulation. However, the experiments performed ex vivo on the vaginal tissue collected
from pregnant sheep highlighted the positive effect of PEGylation on interferon alpha-2b
mucus penetration. Moreover, the absence of interaction between the PEGylated liposomes
and mucin was also demonstrated, confirming this system as an interesting strategy to
improve the efficacy of vaginal anti-viral therapy [68].
As previously mentioned, human cervical cancer can be induced by the expression of
particular types of HPV oncogenes. Thus, to knockdown the sequence-specific genes is
deemed a novel therapeutic approach to contrast the human cervical cancer.
As an example, in 2020, Zhen et al. developed pH-sensitive cationic liposomes as safe
and efficient carriers of CRISPR/Cas9, a gene-editing agent able to correct errors in the
genome to cancer tissues. In vivo experiments in mice showed that these nanoliposomes
significantly inhibited tumor growth without toxicity. Therefore, this system can be consid-
ered a valuable delivery carrier of nonviral gene editing elements, offering a promising
route to precision medicine-based cancer therapeutics [69].
Another interesting approach, proposed by Furst et al. (2016), is the delivery of siRNA
to the vaginal tissues by means of a polymeric solid mucoadhesive system, loaded with
muco-inert PEGylated lipoplexes, able to be rehydrated by the vaginal fluids to form a
hydrogel. The obtained solid systems (sponges) exhibited adequate characteristics such
as hardness, deformability, and mucoadhesive properties. However, further studies are
required to validate active siRNA sustained release [70].
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Wang et al. (2019) designed a thermosensitive gel obtained from W1/O/W2 multiple
microemulsion and exploited it for siRNA delivery [71]. The microgels obtained by self-
emulsification of multiple microemulsions provided higher mucosal residence time and
greater exposure. Moreover, the W1/O/W2 system helped siRNA transport through
the bio-membrane and increased transfection efficiency due to improved in vitro/in vivo
stability and enhanced endocytosis.
Finally, some studies [72] reported the potential of a vaginal curcumin cream to
eradicate HPV infection, but a drawback is represented by the strong interaction between
curcumin and mucus, which lead to a reduced spread over the mucosa. To overcome this
shortcoming, self-emulsifying drug delivery systems offer an attractive choice for curcumin
vaginal delivery as they confer high mucus permeation and rapid spreading of curcumin
on the vaginal mucosa. Results showed that compared to conventional O/W creams, self-
emulsifying systems are advantageous since they promote curcumin permeation through
the mucus gel layer. For these reasons, they could be proposed for many drugs, which in
this way could extend their therapeutic efficacy after vaginal application.
3.2.3. AIDS
AIDS is a sexually transmitted infection that differs from the previously discussed
vaginal infections because vaginal tissues are not targets of HIV disease but actively
participate in its pathogenesis. Furthermore, there is strong evidence of a relationship
between vaginitis and HIV acquisition.
The last years saw significant progress in the formulations of carrier systems suitable
for the prevention and treatment of HIV infection.
One strategy is represented by the use of nanosystems, having intrinsic antiviral activ-
ity or acting as carriers for antimicrobials. In particular, polymeric NPs were shown to be
able to enhance mucosal distribution and retention of many antiretroviral compounds [73].
As an example, NPs made of biodegradable and non-toxic PLGA, loaded with efavirenz or
saquinavir, exhibited in vitro a strong protection against HIV-1 BaL infection and inhibitory
effects significantly greater than free drug.
A study by Chaowanachan et al. (2013) also demonstrated that the combination of
tenofovir with either efavirenz-loaded or saquinavir-loaded NPs synergized combined
drug effects, emphasizing the potential of NPs in realizing unique drug–drug activities [74].
Polymeric NPs could also be functionalized through surface coating, as in the study
of Das Neves et al. (2013), in which dapivirine-loaded PCL NPs coated with PEO (PEO-
PCL-NPs), sodium lauryl sulfate, or cetyl trimethylammonium bromide were developed.
Test of permeability and retention carried out in cell monolayers and pig vaginal mucosa
showed different results according to the coating type. Overall, PEO-PCL-NPs were the
most effective in increasing microbicide drug residence time at epithelial cell lines/mucosal
tissues [75].
New therapeutic alternatives against HIV-1 diffusion are based on peptides able to
inhibit the HIV-1 fusion in target cells at an early stage. However, such peptides exhibit
some drawbacks, e.g., short half-life, rapid clearance, low bioavailability, and poor ability to
cross the physiological barriers, making them unattractive for the pharmaceutical industry.
To overcome these limits, Ariza-Sáenz et al. (2018) developed glycol chitosan-coated PLGA
NPs, exploiting their ability to incorporate an HIV-1 inhibitor peptide, allowing its release
into the vaginal epithelium. The results confirmed that these NPs are able to permeate
vaginal tissue crossing the vaginal fluid to reach the epithelium and release the peptide
inside, allowing a more easily permeation of HIV-1 inhibitor than the free peptide [76].
However, although nanocarriers are beneficial for the intravaginal delivery of anti-HIV
drugs and siRNA, a continuous release of drugs is not desirable for the prevention of HIV.
In this case, it is preferred that the release from the nanocarrier occurs only during sexual
intercourse in order to avoid unnecessary exposure to the drug and to reduce side effects.
For this purpose, Kim et al. (2018) developed a pH-responsive interconnected porous
polyurethane membrane for intravaginal release of NPs containing acid-labile therapeutic
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agents such as siRNA. As a result, drug release was close to zero at pH 4.5 (normal pH
of the female genital tract), while at pH 7.0, a significant increment of drug release was
observed. Moreover, the electrospun porous pH-responsive polyurethane membrane is
nontoxic for human vaginal epithelial cell line (VK2/E6E7) and human T-cell line and does
not induce inflammation, being a novel biomaterial for “smart” intravaginal delivery of
anti-HIV drug-loaded NPs [77].
In the field of drug delivery, films comprise thin, flexible, soft, and often translucent
polymeric solid strips, in which active ingredients are dissolved or dispersed. After admin-
istration and contact with vaginal fluids, films typically dissolve, decrease their volume,
and become a gel-like fluid. However, films can also be designed to slowly disintegrate.
They exhibit well-documented characteristics such as the ability to co-formulate multi-
ple drugs, good stability upon storage, and high acceptability by women since films are
portable, easy to administer without the need of an applicator, and are known to produce
minimal vaginal leakage.
The application of films as platforms for vaginal administration of nanosystems,
namely, drug-loaded polymeric NPs, is recent, due to the ability of the tight polymeric
matrix that surrounds nanosystems to limit phenomena such as particle aggregation and
segregation, leading to colloidal instability [73]. In a study by Cunha-Reis et al. (2016),
for example, efavirenz-loaded and tenofovir-loaded PLGA NPs were incorporated into
fast-dissolving films. In vivo studies revealed that the association between NPs and film
contributed to enhance drug retention in vaginal tissue, mainly during the first hours after
administration. The presence of both tenofovir and efavirenz at the systemic level was low,
helping to prevent adverse effects and potential toxicity. The NPs-in-film system was also
safe for vaginal administration, even if further studies are required [78]. A similar study
was carried out by Machado et al. (2016). In this case, tenofovir-loaded PLGA/stearylamine
composite NPs were incorporated into a hydroxypropyl methylcellulose/PVA-based film,
resulting in a tenofovir release in a biphasic fashion (approximately 30% in 15 min, fol-
lowed by a sustained drug release for 24 h). Moreover, the incorporation of NPs further
improved the adhesive properties of the film, even if cytotoxicity of both NPs and film was
significantly increased by the incorporation of stearylamine, still remaining at tolerable
levels for tenofovir vaginal delivery [79]. Moreover, comparing single or double-layered
films containing free drug with drug loaded NPs incorporated into double-layered films
resulted in double-layered films significantly reducing drug burst effect as compared to fast
releasing single-layered films. Furthermore, drug release delay was noticeable when drug-
loaded NPs were incorporated into double-layered films, being an interesting approach to
sustain the release of anti-HIV drugs [80].
Gels are the most popular dosage forms used for vaginal drug delivery, mainly due to
their technological acceptability by users, versatility, and low production costs. Carbomers
and hydroxyethyl cellulose are the most commonly gelling agents used [73]. As an example,
Martín-Illana et al. (2019) recently developed vaginal bioadhesive emulgels and/or bigels
to prevent sexual transmission of HIV through the controlled release of tenofovir [81].
Moreover, several studies reported the use of thermosensitive hydrogels based on
chitosan and glycerophosphate, even though the burst release of loaded drugs is becoming
a critical challenge when these types of hydrogels are employed as a drug delivery system.
To overcome this problem, chitosan-glycerophosphate hydrogels containing tenofovir and
Bletilla striata polysaccharide microspheres were developed by Yang et al. In this way,
microspheres could be localized around the administrating target because the hydrogel
can transform itself into semisolid gel after administration. Then, the system continually
releases the drug from the double-component formulation, further extending its releasing
time. Bletilla striata polysaccharide was co-delivered with tenofovir due to its antibacterial,
antitumor, and hemostasis properties and its ability to protect gastric mucosa and to
promote wound healing. Such thermosensitive chitosan hydrogels containing polymeric
microspheres exhibit the potential to be an appropriate formulation for sustained-release
vaginal delivery system [82].
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Similarly, Tian et al. proposed a hybrid thermosensitive hydrogel based on nanosized
layered double hydroxides (LDH) and poloxamer. LDH are clay-based NPs that exhibit
high biocompatibility and enhanced drug delivery efficiency. The aim of the authors was
to load into this hybrid hydrogel both hydrophilic theaflavin and hydrophobic nifeviroc,
dispersing theaflavin into poloxamer solution and intercalating nifeviroc into LDH, form-
ing a complex hydrogel-based microbicide candidate for blocking HIV entry into cells.
In vivo studies demonstrated that this system undergoes rapid sol–gel transition at body
temperature, exhibiting poor mucosal irritation and sustained controlled release of both
hydrophilic and hydrophobic drugs into the blood. Moreover, the local concentration of
both drugs is hundreds times of that observed in blood, promoting its application as a
pre-exposure prophylaxis microbicide during sexual behavior [83].
An increased adhesion and retention time in the vaginal mucosa could also be obtained
by adding a gelling polymer to an O/W microemulsion, as in study by Mirani et al.
(2019). This microemulsion gel was loaded with a curcumin derivative explored for the
prophylaxis of HIV-1 infection. Compared to free drug, the developed system exhibited
a coitus-independent release profile, rapid time-independent intracellular uptake, and
fourfold increase in efficacy, making it a potential candidate capable of prevention of HIV-1
infection associated with unprotected sexual intercourse [84].
As already reported, liposomes have been investigated as a potential vaginal delivery
system, but the liquid nature of the preparation represents a meaningful disadvantage. The
addition of mucoadhesive and polymeric agents that lead to the formation of liposomal
gel formulation could be a promising strategy. In this way, HIV-1 envelope glycoprotein
CN54gp140 could be administered as HIV-1 vaccine through its encapsulation within
neutral, positively, or negatively charged liposomes, as reported in a study by Gupta
et al. (2012). These vesicles were then incorporated into hydroxyethyl cellulose aqueous
gel exhibiting good encapsulation efficiency and suitable mucoadhesive strength. The
possibility to be lyophilized makes this liposomal gel a stable and practical dosage form
suitable for vaginal application [85].
Liposomal hydrogels were also used for the delivery of an interesting drug combina-
tion based on tenofovir and emtricitabine, which demonstrated an interesting co-action in
pre-exposure prophylaxis. Due to the yield strong impairment at the polar head groups
of lipid bilayers exhibited by emtricitabine, the final formulation developed by Faria et al.
(2019) consisted of liposomes loaded with tenofovir further incorporated in carbomer-based
hydrogels with emtricitabine. Limitations as leakage and messiness can usually be mini-
mized by simply using lower volumes of gel per administration [86]. Moreover, compared
to emulsions, liposomal gels allow higher drug incorporation, are stable upon storage, and
are well-tolerated and non-irritating after vaginal administration. In addition, drugs are
more absorbed from liposomal formulations than from emulsions or gels, which may be
advantageous when systemic absorption after vaginal administration is required [87,88].
Nanofibers are a solid dosage form that could help to overcome messiness and leakage
characteristics of liquid or gel-based dosage forms. In particular, electrospun nanofibers
can incorporate a remarkable drug amount, up to 60% by mass, and their polymer ratios
and core-shell structure can be modified to control drug release over time for days or weeks.
Moreover, nanofibers exhibit the ability to encapsulate different agents, show flexibility in
processing parameters, and have multiple conceptual geometries to achieve practical and
user-friendly administration. Indeed, Krogstad and Woodrow (2014) hypothesized that
PVA fibers might be a good candidate for a quick-dissolving peri-coital microbicide due to
the amorphous domains of PVA, which allow for swelling and dissolution in water, and the
large surface area, which may further promote fast dissolution and drug release. Using only
water as a solvent, 60% wt/wt tenofovir was encapsulated into electrospun fibers without
compromising fiber integrity. The results revealed that high crystallinity of drug solid
dispersion may not significantly modify release kinetics of tenofovir from electospun fibers,
but it may influence biodistribution by reducing drug solubility. However, nanofibers’
favorable characteristics support the potential for scale-up of tenofovir-loaded fibers [89].
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The positive properties of nanofibers could also be exploited to overcome some NP
challenges such as poor retention and extensive leakage. In a recent study (2017), Krogstad
et al. developed a NP-releasing nanofiber delivery platform, tailoring the two components
in order to obtain optimal interactions with mucus. Mucoadhesive fiber for better retention
in the vaginal tract and PEGylated PLGA NPs that diffuse quickly through mucus were
designed, with PVA and PVP chosen as mucoadhesive polymers. To demonstrate the utility
of this dual system for HIV prevention, the authors also compared the pharmacokinetics of
etravirine from NP–nanofiber composites with those from aqueous suspensions. Actually,
NP–nanofibers composites significantly enhanced both NPs and drug retention in the
reproductive tract compared to the aqueous suspensions; in addition, they ensured a
sustained drug release up to three days after a single administration, overcoming a major
challenge in vaginal delivery of anti-HIV drugs [90].
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3.3. Vaginal Drug Delivery Systems for Fungal Infections
Vulvovaginal Candidiasis
In the last years, novel approaches have been explored for the delivery of antifun-
gal agents—most significantly, vesicular drug delivery systems, nano-particulate-based
carriers, and in situ gelling systems (Figure 4). They offer several advantages such as
targeted delivery, drug protection from degradation, and better drug solubilization and
bioavailability. Moreover, these innovative systems act as a depot system, prolonging drug
release over time with the advantage of dose reduction and increase of patient compliance.
As already reported, in situ gelling systems refer to a class of gels in which stimuli such
as change in pH, change in temperature, or change in solvent induce the gel formation [91].
Indeed, before body administration, they are in sol form, but when administered, they
undergo gelation in situ, forming a gel from which drugs are released in a sustained and
controlled manner. In situ gels represent an attractive system for bioactive molecules, due
to the similarity between their physical properties and those of living tissue that is high
in water content, is soft and rubbery in consistency, and has low interfacial tension with
water/biological fluids. Thanks to their properties, they could increase patient compliance
and exhibit good stability and biocompatibility. Moreover, the production of these devices
is quite easy and requires a low manufacturing cost.
For these reasons, in situ gelling systems can be considered a valuable topical dosage
form for the treatment of vaginal infections. With this aim, in 2019, Patel et al. developed
and characterized pH/temperature-dependent in situ vaginal gel loaded with clotrimazole.
The results showed that all developed formulations exhibited a gelation temperature
between 27 and 35 ◦C. This value decreased with the increment of mucoadhesive polymer
concentration, and the nature of the formed gel depends on the concentration of the
polymers used. All the tested samples had gelling time in the 2–34 seconds range. In
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summary, developed systems were simple and easy to use, syringable, allowed easy
insertion of gel formulation into the vagina, and were able to release clotrimazole in a
controlled way for a prolonged period of time [92].
The incorporation of nanomaterials in hydrogels is an innovative approach to obtain
hydrogel systems with additional properties recently exploited by some researchers for the
vaginal delivery of drugs.
In a recent study, Ci et al. [93] proposed amphotericin B nanosuspension-loaded
thermogel as a strategy to satisfy both drug loading and drug diffusion into vaginal mucus.
The system containing Poloxamer P407/P188 was characterized by thermosensitivity,
high drug loading, and sustained drug release. This formulation resulted in a gelation
temperature around 31 ◦C. In this way, the system was a sol during vaginal administration
and turned to a gel in situ at body temperature. Moreover, the system was stable during
storage and was easy for quality control and large-scale production, allowing a sustained
release for about 12 h. The in vivo anti-Candida albicans assay confirmed that the antifungal
efficiency of amphotericin B nanosuspension-loaded thermogel was better than that of
commercial amphotericin conventional forms, being promising for the development of
other hydrophobic antifungal drug-loaded formulations.
As poloxamers have high aqueous solubility, fast dissolution, and unstable rheological
properties, it is necessary that the association of poloxamers with other polymers such
as sodium alginate are able to improve the mechanical and mucoadhesive properties of
thermosensitive gels. For this reason, Querobino et al. prepared voriconazole organogel
systems based on the incorporation of an oil phase in a poloxamer (Pluronic F127 and F68,
alone or in association) sodium alginate aqueous phase. All the formulations exhibited
thermosensitive behavior and the addition of sodium alginate influenced drug release
in a concentration-dependent way. Organogels developed with Pluronic F127 and F68
association showed good antifungal activity and low cytotoxicity, being a potential new
tool for future vaginal application [94].
Most of the antifungal agents (including voriconazole) are slightly water soluble
and poorly stable in aqueous solution. It seems that the use of inclusion complexes
of drug with hydroxypropyl-beta-cyclodextrin could overcome these limits. It is also
reported that these complexes can increase drug permeation through skin and mucosal
layers. In the literature, a study is reported (2019) in which Deshkar et al. prepared
voriconazole–hydroxypropyl-beta-cyclodextrin inclusion complex to improve aqueous
solubility and stability of voriconazole. This inclusion complex was then incorporated
into in situ gelling systems made of poloxamers. Moreover, the effect of the addition
of various co-adhesive polymers such as hydroxypropyl methyl cellulose, hydroxyethyl
cellulose, and carrageenan was investigated. These developed systems showed good
mucoadhesive strength, sustained drug release (more than 8 h), and higher in vivo vaginal
tissue uptake/drug dispersion in rats compared to conventional in situ gel, confirming the
potential use of such carriers for effective drug delivery [95]. In a similar work (2019), a
multifunctional carrier for ketoconazole, obtained via encapsulation of ketoconazole/β-
cyclodextrin co-ground mixture into chitosan/gellan gum gel flakes, was developed. In a
second step, the developed gel flakes were loaded into an in situ gel of Pluronic F127. The
obtained system resulted in a free-flowing liquid at administration time, enhancing the
spreading and coating of all the vaginal mucosa, and immediately converted into gel in
response to vaginal temperature. Ketoconazole solubility and penetration capacity were
also improved. Noteworthy is the possibility to use lower dose regimen of ketoconazole,
which improves patient compliance and reduces undesirable side effects [96].
Recently, lecithin microemulsion-based lipogels have gained more attention due to
their unique characteristics. Their matrix is composed of lecithin, which acts as a surfactant
and as a gelling agent in the presence of a nonpolar organic solvent as external phase and a
polar agent such as water. These microemulsion gels are thermodynamically stable and
biocompatible, offering a superior resistance to microbial contamination. They have low
cost of preparation, have higher loading efficiency and storage stability, and do not require
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organic solvents. Moreover, lecithin microemulsion-based lipogels could solubilize both
hydrophilic and hydrophobic drugs and exhibit better performance than liposomal gels,
e.g., safety and non-irritant potential, when topically applied. However, more studies are
required to investigate their potential ability to eradicate VC in vivo [97].
Nanoemulsions are nanometric dispersions of two immiscible phases that are capable
of solubilizing lipophilic and hydrophilic drugs, which provide several advantages such
as reduced droplet size, large surface area, good tissue contacts, high drug permeation
into the tissue, and easy/low-cost preparation. Soriano-Ruiz et al. developed clotrimazole-
loaded nanoemulsion to increase drug permeation through mucosae and achieve high and
prolonged levels of clotrimazole for an extended period, avoiding the bloodstream and re-
ducing side effects. In actuality, clotrimazole-loaded nanoemulsion seems to provide higher
deposition on mucosae and antifungal efficacy compared to commercially available clotri-
mazole formulations [98]. Nanoemulsions could also be used as a carrier for amphotericin
B, providing increased drug release and effective therapeutic potential in comparison with
free drug solution and commercial products. Furthermore, this nanocarrier can facilitate
the permeation flux and increase drug permeation rate and deposition [99].
A similar system is represented by multiple W1/O/W2 emulsions, which can be
formed by phase inversion of a simple emulsion and that are of high interest due to their
structures and properties, e.g., protection of the included drug and ability to provide
sustained release. Nevertheless, generally multiple emulsions are characterized by low sta-
bility that can be increased by a combination of polymeric and low lipophilic co-emulsifiers.
In a research article published in 2016, multiple W1/O/W2 emulsions have been proposed
as innovative and stable carriers for imidazolic antifungal drugs, e.g., clotrimazole [100].
Solid lipid NPs are sub-micron range colloidal carriers made of a biocompatible lipid
dispersed in water or in an aqueous buffered solution. Controlled and targeted drug
release, increased stability, high drug entrapment, easy scale-up, and biocompatibility are
some of the advances provided by solid lipid NPs [91]. Some studies report the possibility
to enhance antifungal drugs bioavailability using these nanocarriers. In a study reported
in the literature [101], the authors developed clotrimazole-loaded solid lipid NPs, which
also contained alpha-lipoic acid (able to reduce the generation of reactive oxygen species),
in order to obtain a synergistic treatment for Candida albicans infection. Moreover, the
same NPs were also coated with a cationic lipid; both uncoated and coated NPs exhibited
high homogeneity, reduced mean particles size, and high physical stability with good
drug entrapment into the lipid inner matrix. A slow and constant drug release occurred,
without burst release; moreover, the presence of alpha-lipoic acid did not alter clotrimazole
antimicrobial effectiveness, making this system a promising strategy that could also take
profit of the protective effect of alpha-lipoic acid in the treatment of VC.
Unlike solid lipid NPs, polymeric NPs do not contain a lipid matrix, but are made of
synthetic or natural polymers, e.g., polyacrylamide, polyacrylate, chitosan, or gelatin, as
previously reported [91].
In 2018, Martínez-Pérez et al. prepared clotrimazole-loaded PLGA NPs as vaginal
delivery systems for antimycotic drugs, as PLGA bioadhesivity is lower than that required
to achieve efficient therapy through vaginal administration. The surface of PLGA NPs was
modified with chitosan to improve their mucoadhesivity. A bi-phasic drug release profile
was observed for both modified and unmodified NPs for 18 days, and the presence of
chitosan enhanced the microbicidal and bioadhesive properties of the carrier by increasing
clotrimazole effectiveness against Candida albicans and the interaction with mucin. Further-
more, both modified and unmodified systems are biocompatible and safe [102]. Similar
results were obtained using PCL as polymeric matrix [103].
Liposomes have been investigated for vaginal delivery of antifungal agents. As it is
known, their liquid nature is unfavorable for the applicability in vaginal delivery. Therefore,
mucoadhesive Carbopol resins and chitosan, which are compatible with liposomes, are
frequently used to increase the viscosity of liposomal preparation for the vaginal delivery
of calcein, chloramphenicol, acyclovir, clotrimazole, and metronidazole [104]. In a study
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by Berginc et al., curcumin-loaded chitosan/Carbopol-coated liposomes were developed
to obtain the highest curcumin tissue retention and the lowest tissue permeability. Bioad-
hesive liposomes resulted in being a better drug delivery system for curcumin targeting
vaginal mucosa than free drug solution and non-coated liposome. In fact, both chitosan and
Carbopol coatings significantly increased curcumin permeability through vaginal mucus
in vitro. These results make liposomes an interesting carrier over conventional dosage
forms [105]. Liposomes were also included in a tablet dosage form, suitable for vaginal
administration, as reported in a study by de Jesús Valle et al. (2018), wherein a liposomal
formulation was designed and evaluated for the simultaneous delivery of fluconazole and
itraconazole with d-alpha-tocopheryl polyethylene glycol 1000 succinate, a safe adjuvant
approved by the FDA, used as an emulsifier, solubilizer, antioxidant, and vitamin E supple-
ment. Due to its surfactant effects, this additive promotes tablet disintegration, leading to a
rapid release of both fluconazole and itraconazole and facilitating the prevention of fungal
biofilm [106].
Micro- and nanocapsules are further interesting drug delivery systems for antifungals,
especially via transmucosal administration, since they ensure high surface area, small
size, improved stability of incorporated drugs, ability to protect poorly water-soluble
drugs against chemical or enzymatic degradation, enhanced bioavailability, and controlled
release [107]. Chitosan-coated nanocapsules containing tioconazole and econazole were
developed for vaginal administration, revealing high encapsulation efficiency (more than
87%), stability over two months, and antifungal activity against Candida albicans at non-toxic
concentration for human keratinocyte cell line [108]. Moreover, microcapsules, offering
uniform dispersion in the targeted site, reproducible drug adsorption, and reduced local
irritation, were also used for the delivery of some hydroalcoholic extracts with proved
antioxidant and antifungal activity. In a study by Moreno et al. [107], electrosprayed
chitosan-based microparticles were developed for the vaginal administration of selected
medicinal plant extracts whose biological properties were not affected by the system. A
different release rate of the compounds, better solubility of the extracts, and increased
bioavailability in the vaginal environment were observed. When poloxamers were present
in microparticles formulation, drug solubility/availability and microparticle bioadhesion
to the mucosal tissue increased. In fact, their ability to adhere to the vaginal mucosa
for a prolonged period of time improved the treatment of localized infection, reducing
administration frequency compared to commercial vaginal cream [109]. Gupta et al. [110]
developed vaginal tablets containing clotrimazole-loaded microspheres using bioadhesive
polymers such as hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, and
Carbopol to obtain a prolonged therapeutic activity at the site of infection. In vitro studies
of bioadhesive strength and adhesion time showed the capacity of these tablets to adhere
to the vaginal mucosa for a long period of time, improving drug availability. Consequently,
the formulation is easy to administer, simple, and comfortable, allowing for a possible
controlled clotrimazole release.
Micro- and nanocapsules might also be used to load films and, as for the above-cited
treatment of viral infections, they can be considered a promising approach in treatment
of VC.
Bassi et al. (2015) developed carboxymethyl derivative or fenugreek gum, a galac-
tomannan polysaccharide obtained from seeds of Trigonella foenum-graecum, which possess
film forming properties and bioadhesive potential. Then, films were loaded with nystatin
demonstrating good hydrophilic and swelling properties. Nystatin-loaded film with 5%
wt/wt carboxymethyl derivative or fenugreek gum and 2% v/v glycerol can provide 100%
drug release over 5 h, demonstrating that drug release mechanism is a combination of
diffusion and swelling. This system is non-toxic to vaginal mucosa with good antifungal
properties in vivo, representing a compact, elegant, and patient acceptable dosage form for
mucosal administration [111]. Recently, Calvo et al. (2019) developed drug-loaded vaginal
films composed of chitosan alone or in association with hydroxypropyl methylcellulose
using different amounts of PEG as plasticizer. These films are able to swell for 24 h without
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disintegration and they exhibit faster activity against Candida albicans when compared to
free drug or drug-loaded ovules. Better results were obtained in the presence of hydrox-
ypropyl methylcellulose as a controlled drug release, and a sustained antimicrobial activity
was observed. Furthermore, this formulation did not produce cytotoxic effects, making it a
promising alternative dosage form for the treatment of VC [112].
Despite the many advantages of films, emerging electrospun nanofibers seem to be
even more promising as vaginal delivery systems, as reported in a work by Nematpour et al.
(2020) [113]. In this study, clotrimazole-loaded nanofibers fabricated with an innovative
mucoadhesive formulation of dextran and alginate were developed. Alginate was chosen
for its biodegradability, non-immunogenicity, hydrophilic properties, and pH sensitivity.
Moreover, to avoid the formation of beads or undesirable fibers, the addition of some
solvent or surfactant to the alginate solution might be a solution. Results show that
physicochemical, mechanical, and cytotoxic properties of clotrimazole-loaded nanofibers
are similar to those exhibited by vaginal films, but drug-loaded nanofibers have better
bioadhesion and higher antifungal properties. For this reason, the proposed system appears
more favorable than its film for in vitro vaginal clotrimazole delivery. In another study,
amphotericin B-loaded electrospun PLGA nanofibers were designed to eliminate systemic
adverse effects, fungal resistance, drug interactions, and patient non-compliance. From
the results, it appears that amphotericin B was released in a controlled manner over a
prolonged period (8 days) as a result of entrapped drug diffusion and of the polymer
erosion. The controlled release caused the eradication of vaginal fungal burden after 6 h in
60% of infected rats and did not induce systemic toxicity. Moreover, they did not induce
fungal resistance and patient non-compliance, representing an alternative therapy for local
treatment of vulvovaginal candidiasis [114].
Sponges are a dispersion of gas in a solid matrix able to create a solid porous structure,
providing a potential system for local mucosal surface drug delivery. They can maintain
their swollen hydrogel structure for a long period of time and allow prolonged residence
time and effective drug absorption. Their porous nature and high surface area could
provide a higher drug loading compared to the thin films. The efficiency of this system
can be increased using mixed polymeric systems. In 2018, Shaker et al. formulated
mucoadhesive vaginal sponges loaded with butoconazole nitrate, which were found to be
highly stable for three months and significantly effective against vaginitis/vulvovaginitis
compared to other types of sponges as well as free drug. These carriers might be an
alternative tool to other commercially available vaginal antifungal systems because of their
longer residence time, their improved patient compliance, and their ability to target the
antifungal drug at the site of infection [115]. Microsponge matrix is formed by a huge
number of interconnecting pores in a non-collapsible structure. After the application
in the mucous membranes, microsponges remain in the small pores, where they slowly
release the entrapped substances. They could be considered safe because they do not
reach the systemic circulation. Moreover, thanks to their small pore diameter, bacterial
cells with a size range from 0.007 to 0.2 µm cannot infiltrate into the microsponge cavities.
Moreover, the controlled release of microsponges prevents the accumulation of a great
drug amount in the application site, decreasing the potential skin irritation. Salah et al.
developed a vaginal microsponge system for the delivery of miconazole, which displayed
a desirable flowability and release rate with an in vitro antifungal activity comparable to
the marketed product. In the presence of Carbopol, the retention of the dosage form in
the vagina was further prolonged, increasing the contact time of the drug with the vaginal
mucosa and improving the therapeutic efficiency. More studies on humans are required
to investigate the efficacy, compliance, and side effects [116]. In another study, cellulosic
derivative lyophilized sponges were developed for the delivery of cidofovir, revealing good
mucoadhesive strength. The optimally lyophilization temperature should be 35 ◦C in order
to avoid the formation of large ice crystals that could further damage the incorporated
cidofovir. Moreover, if well formulated, this system could exhibit a dry solid form, be able
Nanomaterials 2021, 11, 311 22 of 29
to protect the entrapped drug, and be easy to handle, with a low rehydration speed in
cervicovaginal mucus, a good mucoadhesive strength, and an optimal viscosity [117].
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3.4. Vaginal Drug Delivery Systems for Parasitic Infections
Trichomoniasis
Currently, 5-nitroimidazole drugs are used for treatment of trichomoniasis by oral and
parenteral routes. Howeve , drug resistance em rgence and i tolera ce to nitroimidazoles
con ribute to increase th in erest in new strategies to fight against this disease. Lately,
sev ral efforts hav been made in developing local treatments of trichomoniasis cases.
The most common local devices used in the treatment of trichomoniasis display sev-
eral disadvantages for microbicide delivery because t ey are generally limited to delivery
of low molecular weight, hydrophobic drugs, e.g., dapivirine, and their production requires
heating at high temperatures (80–160 ◦C), which could egrade thermally sensitive active
compounds. Consequently, researchers have focus d their attention on no el mucoadhe-
sive polymer formulations and matrices to improve the biodistribution of anti-Trichomonas
compounds. Fernando et al. (2019) developed microporous PCL matrices for the vaginal
delivery of tinidazole. In vitro experiments show high loading of tinidazole that is grad-
ually released (until 50%) over 7 days into simulated vaginal fluid with highly retained
antiprotozoal activity. However, additional in vitro studies are necessary to evaluate the
flexural properties and the insertion/retention characteristics of these matrices [118].
Another class of nanocarriers that could be exploited for the treatment of trichomo-
niasis is represented by liposomes. Li et al. developed fibrauretine-loaded propylene
glycol-embodying deformable liposomes. Fibrauretine is an isoquinoline alkaloid isolated
from the rattan of Fibraurea recisa Pierre. It has a noteworthy anti-Trichomonas vaginalis
activity but low oil/water partition coefficient, which makes it difficult to pass through
the vaginal epithelium and diffuse into the vaginal mucosa where pathogens are present.
The encapsulation into deformable liposomes can enhance the permeation of fibrauretine
through vaginal mucosa, allowing high in situ levels and avoiding the absorption into
systemic circulation. In this way, a vaginal local targeting effect is obtained, and toxic drug
adverse effects are reduced. In addition, these fibrauretine-loaded deformable liposomes
are non-irritant and well tolerated in vivo. All this evidence demonstrates the promising
activity of these developed systems and should especially be supported in the future [119].
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Table 3 summarizes the strategies discussed above that have been developed to treat
vaginal infections through the topical route. The main characteristics and applications are
briefly described.
Table 3. Main innovative strategies for the vaginal delivery of antimicrobials agents.
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Suitable mechanical and release
properties, good vaginal retention,
enhanced permeation/penetration,
able to form a physical barrier
Treatment of vaginal infections
(e.g., Chlamydia trachomatis),







Viscous, enhanced vagina retention,
pseudoplastic or thixotropic
behavior that aids dosage spreading,
in some cases stimuli-responsive
properties, easy production,
sustained release, biocompatible
Treatment of Chlamydia trachomatis,
HIV, sexual transmitted infections,





High drug accumulation, promising
outcomes, good drug release,
non-cytotoxic
Treatment of vaginal infections
(HIV)
Nanoemulsions [120] Curcumin, clotrimazole
Very stable; good dissolution rate,
solubility, and bioavailability;
easily applied







Sustained release, increased uptake
into cervical tissue, poor toxicity,
better penetration and diffusion
Viral and sexually transmitted
infections (HIV, HSV), Candida
albicans infections







Loaded with microspheres; precise
dosing; good drug stability;
avoidance of antimicrobial agents for
preservation; easy handling, storage,
and administration; low cost
Treatment of vaginal infections
(e.g., Candida albicans)
4. Conclusions
Conventional therapies in the treatment of vaginal infections generally consist of
systemic or local administration of antimicrobial agents. However, they have several
limitations, including side effects, drug resistance, and infection resistance. In this context,
demand for new alternatives is increasingly relevant.
Recently developed strategies include administration of antimicrobial agents through
the vaginal route providing reduced drug doses, convenient administration, and improved
compliance. Unfortunately, the major challenges for intravaginal drug delivery are the low
residence time and the presence of a complex mucus barrier limiting drug permeation. The
advent of nanotechnology significantly enhances mucoadhesive properties and vaginal
retention of local dosage forms with consequent increased drug permeation. In addition,
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nanoscale systems have been potentially useful in developing innovative preventive and
diagnostic tools that are able to manage vulvovaginal infections.
In conclusion, this review highlights the advantages of nanomaterial-based systems
that can facilitate the development of new approaches and opening new opportunities in
the area of vaginal infections.
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